Cart
sales@molnova.com
PF-06873600
CAS No. 2185857-97-8
PF-06873600( PF06873600 | PF 06873600 )
Catalog No. M13486 CAS No. 2185857-97-8
PF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 254 | Get Quote |
|
| 10MG | 403 | Get Quote |
|
| 25MG | 762 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | 1377 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF-06873600
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
-
DescriptionPF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively; demonstrates potential antineoplastic activity, incerease apoptosis and inhibits umor cell proliferation.Breast Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsPF06873600 | PF 06873600
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number2185857-97-8
-
Formula Weight471.524
-
Molecular FormulaC20H27F2N5O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 83.33 mg/mL 176.73 mM
-
SMILESO=C1C(C(F)F)=CC2=CN=C(NC3CCN(S(=O)(C)=O)CC3)N=C2N1[C@H]4[C@](C)(O)CCC4
-
Chemical NamePyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PHA-848125
A potent, selective, brain penetrant and orally available dual CDK and TRK inhibitor with IC50 of 45 and 53 nM for CDK2/cyclin A and TrkA, respectively; shows cross-reactivity with other CDKs (CDK1/4/5/7), TrkB/C, Kit, Abl and PDGFR (IC50s<1 uM).
-
BLU-222
BLU-222 is an orally available but selective cell cycle protein-dependent kinase (CDK2) inhibitor with antitumor activity for the study of ovarian and uterine cancer.
-
CDK9-IN-15
CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.
